RenovoRx Corp (RNXT) Total Debt to Capital

RenovoRx - graphic logo of issuer RNXT

RenovoRx, Inc. (RNXT) efficiency relies on the precise transportation of complex catheters and medications to hospitals. The company is implementing targeted chemotherapy methods in clinics, creating long-term demand for high-margin consumables. Production capacities and contract sites are fully prepared for volume growth without interruptions. The asset value tracked on the chart, characterizing the total debt-to-equity ratio, stands at 0.04.

renovorx.com (RNXT): Debt to Equity Ratio from 07/04/2022 to 11/01/2026

Metric breakdowns and analytics for RenovoRx Corporation (RNXT)

- share price and consensus valuation forecast:
Stock Price RenovoRx|RNXT - Consensus Target
- market capitalization details:
Market Capitalization RenovoRx|RNXT - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share RenovoRx|RNXT - Accounting Capitalization|Market Capitalization to Book Value Ratio renovorx.com|RNXT - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital RenovoRx, Inc.|RNXT - Long-Term Liabilities to Capital|Short-Term Debt to Equity RenovoRx, Inc.|RNXT - Aggregate Debt Obligations|Debt to Book Value RenovoRx|RNXT - Company Long-Term Loans and Borrowings|Company Short-Term Debt RenovoRx|Quick Liquidity Indicator renovorx.com
- net income and valuation ratios data:
RNXT - Profit After Payment of Taxes
Fundamental company valuation:RenovoRx
Finished products of RenovoRx, Inc.

For RenovoRx, Inc. (RNXT), which depends on clinical trial outcomes and R&D burn rates, maintaining control over financial stability is critical. This ratio, calculated as total liabilities to equity, determines the business's degree of dependence on borrowed capital and the associated bankruptcy risks. By analyzing the shifting proportion of total debt to equity, an investor assesses the balance between the credit load and the company's financial autonomy.

Competitor analysis for RenovoRx, Inc.

TLSI (TriSalus Life Sciences, Inc.) - Total Debt to Capital|Total Debt to Equity Ratio PharmaCyte (PMCB)